Patient Diagnoses

Tom Benzoni benzonit at GMAIL.COM
Wed Nov 22 21:20:33 UTC 2017


That would be easily done, but the conversation has to be safe.
tom

On Wed, Nov 22, 2017 at 2:28 PM, Robert Bell <
0000000296e45ec4-dmarc-request at list.improvediagnosis.org> wrote:

> Dear list members,
>
> I have been interested in the recent discussions about diagnostic problems.
>
> However, I wondered if there might be more comment, more interest if the
> arguments were illustrated by examples. I wondered if we might learn
> something if, for example, the difficulties of diagnosing a Myocardial
> infarction were compared to say a Takotsuba cardiomyopathy (which I
> understand is not too uncommon).
>
> Then I said to myself, is the reluctance to talk about the actual clinical
> situation in our discussions in some way governed by privacy considerations
> - and in the US the confining HIPPA regulations.
>
> But there should be a way to overcome that by using fictitious stories,
> modified stories to preserve privacy, very old stories, etc., etc.
>
> Would some list guidelines help and get us closer to the actual patient in
> our deliberations?
>
> HAPPY THANKSGIVING TO ALL.
>
> Rob Bell, MD
>
>
>
>
>
> ------------------------------
>
>
> To unsubscribe from IMPROVEDX: click the following link:
> http://list.improvediagnosis.org/scripts/wa-IMPDIAG.exe?
> SUBED1=IMPROVEDX&A=1 or send email to: IMPROVEDX-SIGNOFF-REQUEST@
> LIST.IMPROVEDIAGNOSIS.ORG
>
> Moderator:David Meyers, Board Member, Society for Improving Diagnosis in
> Medicine
>
> To learn more about SIDM visit:
> http://www.improvediagnosis.org/






Moderator: David Meyers, Board Member, Society to Improve Diagnosis in Medicine

To unsubscribe from the IMPROVEDX list, click the following link:<br>
<a href="http://list.improvediagnosis.org/scripts/wa-IMPDIAG.exe?SUBED1=IMPROVEDX&A=1" target="_blank">http://list.improvediagnosis.org/scripts/wa-IMPDIAG.exe?SUBED1=IMPROVEDX&A=1</a>
</p>

HTML Version:
URL: <../attachments/20171122/3c7223ea/attachment.html>


More information about the Test mailing list